Maurilio Ponzoni

Active 1997–2025

170
Papers
30,110
Citations
95
h-index
165
i10-index

Citations

Citations per year for Maurilio Ponzoni1991: 3 citations1994: 1 citations1997: 1 citations1998: 11 citations1999: 12 citations2000: 11 citations2001: 12 citations2002: 20 citations2003: 34 citations2004: 39 citations2005: 63 citations2006: 103 citations2007: 109 citations2008: 128 citations2009: 150 citations2010: 203 citations2011: 203 citations2012: 190 citations2013: 263 citations2014: 244 citations2015: 304 citations2016: 275 citations2017: 261 citations2018: 295 citations2019: 971 citations2020: 1,042 citations2021: 1,050 citations2022: 777 citations2023: 567 citations2024: 913 citations2025: 391 citations2026: 14 citations1992–1993: no citations, so these years are not shown1995–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,997 citing papers, 26.2% of this breakdownChina: 1,144 citing papers, 10% of this breakdownItaly: 961 citing papers, 8.4% of this breakdownGermany: 831 citing papers, 7.3% of this breakdownUnited Kingdom: 699 citing papers, 6.1% of this breakdownFrance: 559 citing papers, 4.9% of this breakdownSpain: 389 citing papers, 3.4% of this breakdownSwitzerland: 381 citing papers, 3.3% of this breakdownCanada: 350 citing papers, 3.1% of this breakdownJapan: 312 citing papers, 2.7% of this breakdownNetherlands: 298 citing papers, 2.6% of this breakdownAustralia: 213 citing papers, 1.9% of this breakdown
0%26.2%Other 20.1%

Fields

  • Medicine65.9%
  • Biochemistry, Genetics and Molecular Biology23.1%
  • Immunology and Microbiology8.9%
  • Neuroscience1%
  • Engineering0.3%
  • Computer Science0.2%
  • Other0.6%

Topics

  • Lymphoma Diagnosis and Treatment9.4%
  • CAR-T cell therapy research8.8%
  • Immune Cell Function and Interaction4.9%
  • CNS Lymphoma Diagnosis and Treatment3.8%
  • Virus-based gene therapy research3.8%
  • Chronic Lymphocytic Leukemia Research2.9%
  • Other66.4%

Coauthors

All papers

Open in search
  1. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

    Authors: , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 1,380

  2. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2022 cited by 220

  3. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome

    Authors: , , , , , , , , , , , , , , , , , - 2022 cited by 167

  4. Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses

    Authors: , , , , , , , , , , , , , , , , , - Nature Medicine 2009 cited by 330

  5. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2013 cited by 352

  6. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2019 cited by 152

  7. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alessandro Levis, Hans‐Joachim Schmoll, Franco Cavalli, Jürgen Finke, Michele Reni, Emanuele Zucca, Gerald Illerhaus - The Lancet Haematology 2016 cited by 599

  8. Primary central nervous system lymphoma

    Authors: , , , , , , , , , , - Nature Reviews Disease Primers 2023 cited by 244

  9. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

    Authors: , , , , , , , , , , , , , - Nature 2009 cited by 1,043

  10. Genetics of Follicular Lymphoma Transformation

    Authors: , , , , , , , , , , , , , , , , , , - Cell Reports 2014 cited by 585

  11. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jürgen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, IELSG32 study investigators - Leukemia 2022 cited by 162

  12. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Michael Pfreundschuh, Giuseppina Cabras, F. Angrilli, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jürgen Finke, Michele Reni, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus - The Lancet Haematology 2017 cited by 381

  13. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daina Variakojis, Weina Chen, Ronald S. Go, Miguel Á. Piris, Michael Møller, L. Jeffrey Medeiros, Ken H. Young - Blood 2013 cited by 679

  14. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2003 cited by 840

  15. Plasma cells require autophagy for sustainable immunoglobulin production

    Authors: , , , , , , , , , , , , , , - Nature Immunology 2013 cited by 416

  16. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Miguel Á. Piris, Michael Møller, Roberto N. Miranda, Lynne V. Abruzzo, L. Jeffrey Medeiros, Ken H. Young - Blood 2012 cited by 391

  17. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2012 cited by 444

  18. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , - Annals of Oncology 2020 cited by 341

  19. Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gianluca Gaïdano, Stefano Pileri, Enrico Tiacci, Brunangelo Falini, Leonard D. Shultz, Laurence Mévellec, Jorge Vialard, Roberto Piva, Francesco Bertoni, Raúl Rabadán, Giorgio Inghirami - Cancer Cell 2015 cited by 442

  20. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy

    Authors: , , , , , , , , , , , , , - Journal of Clinical Investigation 2009 cited by 573

  21. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2015 cited by 283

  22. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer

    Authors: , , , , , , , , - Blood 2007 cited by 495

  23. Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2014 cited by 310

  24. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Immunology 2013 cited by 214